Stefan James
Raymond Gibbons
REFERENCE: Hot Line 1 Sunday 11:00 2 Sept, European Society of Cardiology Congress, 2007, 1-5 September, Vienna, AustriaSTEFAN JAMES, Uppsala Clinical Research Centre, SwedenCOMMENT: RAYMOND GIBBONS, Mayo Clinic, Rochester MNAnother year’s results of the long term outcome of using drug-eluting stents as compared with bare-metal stents from Sweden reveal that there is no longer an increased risk of late mortality when using drug-eluting stents according toStefan Jamesof Uppsala Clinical Research Centre. He suggested that improvements in technique have helped reduce the risk of death or myocardial infarction associated with using drug-eluting stents nevertheless the risk of blood clots still remains. Overall survival of patients was found to be the similar for both categories of stent.
Nicola Soloman interviewed Stefan James after his presentation at the European Society of Cardiology meeting in Vienna.Raymond Gibbons, president of the American Heart Association, added his comments.
Tags
Related Episodes
Large Risk Reduction For Rivaroxaban In Blood Clot Prevention
Bengt Eriksson REFERENCE: Abstract 6, American Society of Hematology Annual Meeting, December 8-11 2007, Atlanta BENGT ERIKSSON, Gothenburg University In a large phase III trial of patients having a h
Drug Eluting Stent Shows Great Benefit in Chronic Total Occlusions
Gerald Werner REFERENCE: Abstract 925, European Society of Cardiology Congress, 2007, 1-5 September, Vienna, Austria GERALD WERNER, Klinikum Darmstadt, Germany The ESC congress in Vienna heard that dr
Audio Journal of Global Health Issues: Drug Eluting Stents, PFO Closure: Indications Not Obvious
MARK REISMAN, Swedish Medical Center, Seattle REFERENCE: ABSTRACT ACP Internal Medicine 2007, ERA 002 Drug eluting stents may not always be the automatic choice over the bare metal variety for patient